{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:32:56Z","timestamp":1784698376062,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The CRISPR\/Cas9 system is a recently developed genome editing technique. In this study, we used a modified CRISPR system, which employs the fusion of inactive Cas9 (dCas9) and the <jats:italic>Fok<\/jats:italic>I endonuclease (<jats:italic>Fok<\/jats:italic>I-dCas9) to correct the most common variant (allele frequency 21.4%) in the phenylalanine hydroxylase (<jats:italic>PAH<\/jats:italic>) gene - c.1222C&gt;T (p.Arg408Trp) - as an approach toward curing phenylketonuria (PKU). PKU is the most common inherited diseases in amino acid metabolism. It leads to severe neurological and neuropsychological symptoms if untreated or late diagnosed. Correction of the disease-causing variants could rescue residual PAH activity and restore normal function. Co-expression of a single guide RNA plasmid, a <jats:italic>Fok<\/jats:italic>I-dCas9-zsGreen1 plasmid, and the presence of a single-stranded oligodeoxynucleotide in <jats:italic>PAH<\/jats:italic>_c.1222C&gt;T COS-7 cells \u2013 an <jats:italic>in vitro<\/jats:italic> model for PKU \u2013 corrected the <jats:italic>PAH<\/jats:italic> variant and restored PAH activity. Also in this system, the HDR enhancer RS-1 improved correction efficiency. This proof-of-concept indicates the potential of the <jats:italic>Fok<\/jats:italic>I-dCas9 system for precision medicine, in particular for targeting PKU and other monogenic metabolic diseases.<\/jats:p>","DOI":"10.1038\/srep35794","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T09:40:24Z","timestamp":1477561224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model"],"prefix":"10.1038","volume":"6","author":[{"given":"Yi","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Jung-Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Betzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg F.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg D.","family":"Hoheisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"BFsrep35794_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., Van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417\u20131427 (2010).","journal-title":"Lancet"},{"key":"BFsrep35794_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/humu.22320","volume":"34","author":"C Heintz","year":"2013","unstructured":"Heintz, C., Cotton, R. G. & Blau, N. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase and importance of genotypes for pharmacological therapy of phenylketonuria. Hum Mutat 34, 927\u2013936, 10.1002\/humu.22320 (2013).","journal-title":"Hum Mutat"},{"key":"BFsrep35794_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1586\/14737159.2014.923760","volume":"14","author":"N Blau","year":"2014","unstructured":"Blau, N., Shen, N. & Carducci, C. Molecular genetics and diagnosis of phenylketonuria: state of the art. Expert review of molecular diagnostics 14, 655\u2013671, 10.1586\/14737159.2014.923760 (2014).","journal-title":"Expert review of molecular diagnostics"},{"key":"BFsrep35794_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1101\/gr.173427.114","volume":"24","author":"F Xie","year":"2014","unstructured":"Xie, F. et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR\/Cas9 and piggyBac. Genome Res 24, 1526\u20131533, 10.1101\/gr.173427.114 (2014).","journal-title":"Genome Res"},{"key":"BFsrep35794_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature biotechnology 32, 347\u2013355, 10.1038\/nbt.2842 (2014).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR6","doi-asserted-by":"publisher","first-page":"19969","DOI":"10.1038\/srep19969","volume":"6","author":"AG Bassuk","year":"2016","unstructured":"Bassuk, A. G., Zheng, A., Li, Y., Tsang, S. H. & Mahajan, V. B. Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells. Sci Rep 6, 19969, 10.1038\/srep19969 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep35794_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nbt.2884","volume":"32","author":"H Yin","year":"2014","unstructured":"Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature biotechnology 32, 551\u2013553, 10.1038\/nbt.2884 (2014).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407, 10.1126\/science.aad5143 (2016).","journal-title":"Science"},{"key":"BFsrep35794_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400\u2013403, 10.1126\/science.aad5725 (2016).","journal-title":"Science"},{"key":"BFsrep35794_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411, 10.1126\/science.aad5177 (2016).","journal-title":"Science"},{"key":"BFsrep35794_CR11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature biotechnology 31, 822\u2013826, 10.1038\/nbt.2623 (2013).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt.2916","volume":"32","author":"C Kuscu","year":"2014","unstructured":"Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nature biotechnology 32, 677\u2013683, 10.1038\/nbt.2916 (2014).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR13","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.1038\/srep11221","volume":"5","author":"S Hara","year":"2015","unstructured":"Hara, S. et al. Generation of mutant mice via the CRISPR\/Cas9 system using FokI-dCas9. Sci Rep 5, 11221, 10.1038\/srep11221 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep35794_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nbt.2909","volume":"32","author":"JP Guilinger","year":"2014","unstructured":"Guilinger, J. P., Thompson, D. B. & Liu, D. R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nature biotechnology 32, 577\u2013582, 10.1038\/nbt.2909 (2014).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nbt.2908","volume":"32","author":"SQ Tsai","year":"2014","unstructured":"Tsai, S. Q. et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nature biotechnology 32, 569\u2013576, 10.1038\/nbt.2908 (2014).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR16","doi-asserted-by":"publisher","first-page":"9379","DOI":"10.1093\/nar\/gkv993","volume":"43","author":"J Pinder","year":"2015","unstructured":"Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain \u2018knock-in\u2019 screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic acids research 43, 9379\u20139392, 10.1093\/nar\/gkv993 (2015).","journal-title":"Nucleic acids research"},{"key":"BFsrep35794_CR17","doi-asserted-by":"publisher","first-page":"10548","DOI":"10.1038\/ncomms10548","volume":"7","author":"J Song","year":"2016","unstructured":"Song, J. et al. RS-1 enhances CRISPR\/Cas9- and TALEN-mediated knock-in efficiency. Nature communications 7, 10548, 10.1038\/ncomms10548 (2016).","journal-title":"Nature communications"},{"key":"BFsrep35794_CR18","doi-asserted-by":"publisher","first-page":"15848","DOI":"10.1073\/pnas.0808046105","volume":"105","author":"K Jayathilaka","year":"2008","unstructured":"Jayathilaka, K. et al. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci USA 105, 15848\u201315853, 10.1073\/pnas.0808046105 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep35794_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/metabo4041007","volume":"4","author":"P Strisciuglio","year":"2014","unstructured":"Strisciuglio, P. & Concolino, D. New Strategies for the Treatment of Phenylketonuria (PKU). Metabolites 4, 1007\u20131017, 10.3390\/metabo4041007 (2014).","journal-title":"Metabolites"},{"key":"BFsrep35794_CR20","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.ymgme.2009.10.008","volume":"99","author":"FJ van Spronsen","year":"2010","unstructured":"van Spronsen, F. J. & Enns, G. M. Future treatment strategies in phenylketonuria. Mol Genet Metab 99 Suppl 1, S90\u201395, 10.1016\/j.ymgme.2009.10.008 (2010).","journal-title":"Mol Genet Metab"},{"key":"BFsrep35794_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262\u20131278, 10.1016\/j.cell.2014.05.010 (2014).","journal-title":"Cell"},{"key":"BFsrep35794_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","volume":"85","author":"H Wang","year":"2016","unstructured":"Wang, H., La Russa, M. & Qi, L. S. CRISPR\/Cas9 in Genome Editing and Beyond. Annual review of biochemistry 85, 227\u2013264, 10.1146\/annurev-biochem-060815-014607 (2016).","journal-title":"Annual review of biochemistry"},{"key":"BFsrep35794_CR23","doi-asserted-by":"publisher","first-page":"e0133373","DOI":"10.1371\/journal.pone.0133373","volume":"10","author":"M Aouida","year":"2015","unstructured":"Aouida, M. et al. Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. PLoS One 10, e0133373, 10.1371\/journal.pone.0133373 (2015).","journal-title":"PLoS One"},{"key":"BFsrep35794_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nature methods 11, 399\u2013402, 10.1038\/nmeth.2857 (2014).","journal-title":"Nature methods"},{"key":"BFsrep35794_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84\u201388, 10.1126\/science.aad5227 (2016).","journal-title":"Science"},{"key":"BFsrep35794_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nbt.3190","volume":"33","author":"T Maruyama","year":"2015","unstructured":"Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature biotechnology 33, 538\u2013542, 10.1038\/nbt.3190 (2015).","journal-title":"Nature biotechnology"},{"key":"BFsrep35794_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1203\/00006450-197512000-00006","volume":"9","author":"K Bartholom\u00e9","year":"1975","unstructured":"Bartholom\u00e9, K., Lutz, P. & Bickel, H. Determination of phenylalanine hydroxylase activity in patients with phenylketonuria and hyperphenylalaninemia. Pediatr Res 9, 899 (1975).","journal-title":"Pediatr Res"},{"key":"BFsrep35794_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jsb.2010.06.016","volume":"172","author":"T Unger","year":"2010","unstructured":"Unger, T., Jacobovitch, Y., Dantes, A., Bernheim, R. & Peleg, Y. Applications of the Restriction Free (RF) cloning procedure for molecular manipulations and protein expression. J Struct Biol 172, 34\u201344, 10.1016\/j.jsb.2010.06.016 (2010).","journal-title":"J Struct Biol"},{"key":"BFsrep35794_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nmeth.2812","volume":"11","author":"F Heigwer","year":"2014","unstructured":"Heigwer, F., Kerr, G. & Boutros, M. E-CRISP: fast CRISPR target site identification. Nature methods 11, 122\u2013123, 10.1038\/nmeth.2812 (2014).","journal-title":"Nature methods"},{"key":"BFsrep35794_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2016.01.004","volume":"117","author":"N Shen","year":"2016","unstructured":"Shen, N. et al. Co-expression of phenylalanine hydroxylase variants and effects of interallelic complementation on in vitro enzyme activity and genotype-phenotype correlation. Mol Genet Metab 117, 328\u2013335, 10.1016\/j.ymgme.2016.01.004 (2016).","journal-title":"Mol Genet Metab"},{"key":"BFsrep35794_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/bioinformatics\/btt764","volume":"30","author":"A Xiao","year":"2014","unstructured":"Xiao, A. et al. CasOT: a genome-wide Cas9\/gRNA off-target searching tool. Bioinformatics 30, 1180\u20131182, 10.1093\/bioinformatics\/btt764 (2014).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep35794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35794","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep35794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:29:10Z","timestamp":1672885750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep35794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep35794"],"URL":"https:\/\/doi.org\/10.1038\/srep35794","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]},"assertion":[{"value":"26 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35794"}}